Activity of human β-defensins 2 and 3 against ESBL-producing Klebsiella strains

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 3, 2006, Pages 562-565

  Sahly, Hany ^a   Schubert, Sabine ^a   Harder, Jürgen ^a   Kleine, Michael ^b   Sandvang, Dorthe ^c   Ullmann, Uwe ^a   Schröder, Jens M ^a   Podschun, Rainer ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Planton GmbH   (Germany)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Innate immunity; Klebsiella spp.; Multidrug resistance

Indexed keywords

BETA DEFENSIN 2; BETA DEFENSIN 3; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; NONHUMAN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTI-BACTERIAL AGENTS; BETA-DEFENSINS; BETA-LACTAMASES; HUMANS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE;

EID: 32644451274     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkl003     Document Type: Article

References (12)

1. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998; 11: 589-603.
2. Ko WC, Paterson DL, Sagnimeni AJ et al. Community-acquired Klebsiella pneumoniae bacteremia: Global differences in clinical patterns. Emerg Infect Dis 2002; 8: 160-6.
3. Gikas A, Samonis G, Christidou A et al. Gram-negative bacteremia in non-neutropenic patients: A 3-year review. Infection 1998; 26: 155-9.
4. Gniadkowski M. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001; 7: 597-608.
5. Winokur PL, Canton R, Casellas JM et al. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32: 94-103.
6. Cao VT, Arlet G, Ericsson BM et al. Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmidmediated CMY-4 and permeability alteration. J Antimicrob Chemother 2000; 46: 895-900.
7. Crovella S, Antcheva N, Zelezetsky I et al. Primate β-defensins - structure, function and evolution. Curr Protein Pept Sci 2005; 6: 7-21.
8. Harder J, Bartels J, Christophers E et al. A peptide antibiotic from human skin. Nature 1997; 387: 861.
9. Sahly H, Schubert S, Harder J et al. Human β-defensin 3 has a potent antimicrobial effect against Gram-negative and Gram-positive bacteria, except the Burkholderia cepacia complex. Antimicrob Agents Chemother 2003; 47: 1739-41.
10. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Supplemental Tables M100-S12. NCCLS, Wayne, PA, USA, 2002.
11. Sahly H, Aucken H, Benedi VJ et al. Increased serum resistance in Klebsiella pneumoniae strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 2004; 48: 3477-82.
12. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-9.